Using dynamic microsimulation to project cognitive function in the elderly population

Author:

Wei YifanORCID,Heun-Johnson HankeORCID,Tysinger BryanORCID

Abstract

Background A long-term projection model based on nationally representative data and tracking disease progression across Alzheimer’s disease continuum is important for economics evaluation of Alzheimer’s disease and other dementias (ADOD) therapy. Methods The Health and Retirement Study (HRS) includes an adapted version of the Telephone Interview for Cognitive Status (TICS27) to evaluate respondents’ cognitive function. We developed an ordered probit transition model to predict future TICS27 score. This transition model is utilized in the Future Elderly Model (FEM), a dynamic microsimulation model of health and health-related economic outcomes for the US population. We validated the FEM TICS27 model using a five-fold cross validation approach, by comparing 10-year (2006–2016) simulated outcomes against observed HRS data. Results In aggregate, the distribution of TICS27 scores after ten years of FEM simulation matches the HRS. FEM’s assignment of cognitive/mortality status also matches those observed in HRS on the population level. At the individual level, the area under the receiver operating characteristic (AUROC) curve is 0.904 for prediction of dementia or dead with dementia in 10 years, the AUROC for predicting significant cognitive decline in two years for mild cognitive impairment patients is 0.722. Conclusions The FEM TICS27 model demonstrates its predictive accuracy for both two- and ten-year cognitive outcomes. Our cognition projection model is unique in its validation with an unbiased approach, resulting in a high-quality platform for assessing the burden of cognitive decline and translating the benefit of innovative therapies into long-term value to society.

Funder

National Institute on Aging

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. 2019 Alzheimer's disease facts and figures

2. Alzheimer’s disease drug development pipeline: 2019.;J Cummings;Alzheimer’s & Dementia: Translational Research & Clinical Interventions,2019

3. Approval of Aducanumab for Alzheimer Disease—the FDA’s Perspective.;B Dunn;JAMA Internal Medicine.,2021

4. The End of the Beginning of the Alzheimer’s Disease Nightmare: A Devil’s Advocate’s View.;A. Wimo;Journal of Alzheimer’s disease: JAD.,2018

5. Preparing the health-care system to pay for new Alzheimer’s drugs.;P-J Lin;Alzheimer’s & Dementia.,2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3